| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neglected Diseases | 119 | 2025 | 153 | 39.660 |
Why?
|
| Tropical Medicine | 79 | 2025 | 104 | 20.120 |
Why?
|
| Vaccines | 103 | 2025 | 384 | 19.650 |
Why?
|
| Global Health | 106 | 2025 | 627 | 15.220 |
Why?
|
| Parasitic Diseases | 43 | 2025 | 60 | 13.200 |
Why?
|
| Hookworm Infections | 71 | 2026 | 127 | 13.080 |
Why?
|
| Communicable Disease Control | 50 | 2021 | 141 | 12.260 |
Why?
|
| Communicable Diseases | 38 | 2023 | 158 | 9.420 |
Why?
|
| Helminthiasis | 42 | 2025 | 83 | 9.300 |
Why?
|
| Chagas Disease | 60 | 2026 | 319 | 9.030 |
Why?
|
| Ancylostoma | 63 | 2015 | 99 | 7.560 |
Why?
|
| Antigens, Helminth | 73 | 2025 | 187 | 7.340 |
Why?
|
| Vaccination | 74 | 2025 | 1051 | 7.180 |
Why?
|
| Poverty | 44 | 2025 | 451 | 6.920 |
Why?
|
| Tropical Climate | 36 | 2020 | 51 | 6.500 |
Why?
|
| Necator americanus | 52 | 2026 | 93 | 6.180 |
Why?
|
| Trypanosoma cruzi | 41 | 2026 | 255 | 6.180 |
Why?
|
| Helminth Proteins | 41 | 2025 | 104 | 5.300 |
Why?
|
| Disease Eradication | 19 | 2025 | 39 | 5.280 |
Why?
|
| Developing Countries | 39 | 2021 | 301 | 4.930 |
Why?
|
| Ancylostomatoidea | 37 | 2023 | 60 | 4.860 |
Why?
|
| Vaccines, Synthetic | 49 | 2025 | 319 | 4.850 |
Why?
|
| Pandemics | 35 | 2025 | 1157 | 4.820 |
Why?
|
| Health Policy | 23 | 2020 | 225 | 4.820 |
Why?
|
| Humans | 525 | 2026 | 130374 | 4.470 |
Why?
|
| Measles | 11 | 2025 | 40 | 4.420 |
Why?
|
| Viral Vaccines | 14 | 2020 | 317 | 4.300 |
Why?
|
| Ancylostomiasis | 39 | 2015 | 62 | 4.220 |
Why?
|
| Schistosomiasis | 24 | 2024 | 52 | 4.210 |
Why?
|
| Anti-Vaccination Movement | 9 | 2023 | 11 | 4.000 |
Why?
|
| Coronavirus Infections | 15 | 2020 | 351 | 3.820 |
Why?
|
| Protozoan Vaccines | 26 | 2026 | 101 | 3.810 |
Why?
|
| Trichuriasis | 14 | 2025 | 31 | 3.800 |
Why?
|
| Communicable Diseases, Emerging | 13 | 2025 | 70 | 3.770 |
Why?
|
| Science | 6 | 2021 | 36 | 3.750 |
Why?
|
| Public Health | 26 | 2021 | 272 | 3.690 |
Why?
|
| Animals | 303 | 2026 | 33846 | 3.540 |
Why?
|
| Diplomacy | 5 | 2025 | 5 | 3.490 |
Why?
|
| Malaria | 17 | 2022 | 95 | 3.440 |
Why?
|
| Politics | 12 | 2022 | 59 | 3.430 |
Why?
|
| Anthelmintics | 25 | 2020 | 55 | 3.360 |
Why?
|
| Virus Diseases | 11 | 2020 | 286 | 3.120 |
Why?
|
| Global Burden of Disease | 6 | 2025 | 38 | 3.030 |
Why?
|
| Disease Outbreaks | 16 | 2025 | 314 | 3.020 |
Why?
|
| Spike Glycoprotein, Coronavirus | 18 | 2025 | 216 | 2.990 |
Why?
|
| Antibodies, Helminth | 43 | 2025 | 131 | 2.990 |
Why?
|
| International Cooperation | 15 | 2025 | 160 | 2.980 |
Why?
|
| Biomedical Research | 19 | 2025 | 561 | 2.930 |
Why?
|
| Vaccination Refusal | 5 | 2022 | 19 | 2.890 |
Why?
|
| Necatoriasis | 24 | 2026 | 39 | 2.870 |
Why?
|
| Ascariasis | 19 | 2021 | 77 | 2.840 |
Why?
|
| Recombinant Proteins | 53 | 2023 | 1317 | 2.840 |
Why?
|
| Communication | 9 | 2021 | 540 | 2.740 |
Why?
|
| Helminths | 14 | 2024 | 52 | 2.710 |
Why?
|
| Toxocariasis | 15 | 2020 | 29 | 2.690 |
Why?
|
| Schistosomiasis haematobia | 8 | 2020 | 11 | 2.680 |
Why?
|
| Mass Drug Administration | 10 | 2022 | 14 | 2.680 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 363 | 2.560 |
Why?
|
| Adjuvants, Immunologic | 37 | 2026 | 393 | 2.560 |
Why?
|
| Immunization Programs | 8 | 2021 | 69 | 2.520 |
Why?
|
| World Health Organization | 19 | 2021 | 116 | 2.470 |
Why?
|
| United States | 78 | 2026 | 11864 | 2.330 |
Why?
|
| Protozoan Infections | 9 | 2020 | 15 | 2.280 |
Why?
|
| Intestinal Diseases, Parasitic | 11 | 2020 | 43 | 2.230 |
Why?
|
| Bacterial Infections | 10 | 2020 | 326 | 2.060 |
Why?
|
| Leishmaniasis | 10 | 2023 | 41 | 1.980 |
Why?
|
| Climate Change | 8 | 2025 | 67 | 1.980 |
Why?
|
| Cost of Illness | 21 | 2025 | 293 | 1.960 |
Why?
|
| Periodicals as Topic | 5 | 2017 | 182 | 1.940 |
Why?
|
| Prevalence | 54 | 2025 | 2680 | 1.940 |
Why?
|
| Zika Virus Infection | 8 | 2020 | 174 | 1.840 |
Why?
|
| Vaccination Coverage | 9 | 2025 | 40 | 1.830 |
Why?
|
| Betacoronavirus | 10 | 2020 | 282 | 1.820 |
Why?
|
| Praziquantel | 7 | 2020 | 13 | 1.760 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 3 | 2020 | 13 | 1.750 |
Why?
|
| Nitroimidazoles | 10 | 2026 | 49 | 1.690 |
Why?
|
| Glutathione Transferase | 12 | 2026 | 147 | 1.680 |
Why?
|
| Trachoma | 11 | 2019 | 13 | 1.670 |
Why?
|
| Life Expectancy | 7 | 2025 | 63 | 1.620 |
Why?
|
| Toxocara | 7 | 2020 | 16 | 1.590 |
Why?
|
| Schistosomicides | 4 | 2019 | 4 | 1.590 |
Why?
|
| Mortality | 7 | 2025 | 259 | 1.560 |
Why?
|
| Antiparasitic Agents | 9 | 2022 | 28 | 1.550 |
Why?
|
| Disease Transmission, Infectious | 7 | 2019 | 74 | 1.530 |
Why?
|
| Urbanization | 5 | 2020 | 10 | 1.500 |
Why?
|
| Arbovirus Infections | 6 | 2020 | 30 | 1.480 |
Why?
|
| Attitude to Health | 5 | 2021 | 247 | 1.470 |
Why?
|
| Pregnancy Complications, Parasitic | 6 | 2020 | 26 | 1.450 |
Why?
|
| Protozoan Proteins | 8 | 2026 | 127 | 1.440 |
Why?
|
| Insect Vectors | 7 | 2018 | 113 | 1.370 |
Why?
|
| Epidemics | 6 | 2019 | 57 | 1.370 |
Why?
|
| Genital Diseases, Female | 3 | 2020 | 31 | 1.340 |
Why?
|
| Social Media | 3 | 2024 | 120 | 1.320 |
Why?
|
| Quality-Adjusted Life Years | 15 | 2020 | 126 | 1.290 |
Why?
|
| Women's Health | 6 | 2020 | 133 | 1.290 |
Why?
|
| Albendazole | 10 | 2018 | 26 | 1.290 |
Why?
|
| Zoonoses | 8 | 2020 | 55 | 1.270 |
Why?
|
| Warfare | 6 | 2018 | 33 | 1.270 |
Why?
|
| Cause of Death | 8 | 2025 | 502 | 1.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 6 | 2021 | 218 | 1.250 |
Why?
|
| Schistosoma haematobium | 6 | 2019 | 17 | 1.240 |
Why?
|
| Mice, Inbred BALB C | 33 | 2026 | 977 | 1.240 |
Why?
|
| Pichia | 17 | 2017 | 56 | 1.240 |
Why?
|
| Influenza Vaccines | 3 | 2023 | 501 | 1.230 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 4 | 2025 | 22 | 1.220 |
Why?
|
| Human Rights | 2 | 2020 | 25 | 1.220 |
Why?
|
| Antibodies, Neutralizing | 18 | 2025 | 525 | 1.220 |
Why?
|
| Cloning, Molecular | 25 | 2021 | 780 | 1.220 |
Why?
|
| Aggression | 2 | 2021 | 218 | 1.210 |
Why?
|
| United Nations | 6 | 2021 | 10 | 1.210 |
Why?
|
| Soil | 12 | 2025 | 76 | 1.200 |
Why?
|
| Africa | 16 | 2020 | 139 | 1.200 |
Why?
|
| Socioeconomic Factors | 18 | 2020 | 901 | 1.190 |
Why?
|
| Dogs | 31 | 2022 | 617 | 1.180 |
Why?
|
| Female | 135 | 2026 | 70312 | 1.170 |
Why?
|
| Trichuris | 7 | 2025 | 26 | 1.170 |
Why?
|
| Amino Acid Sequence | 40 | 2021 | 2397 | 1.160 |
Why?
|
| Larva | 36 | 2019 | 244 | 1.150 |
Why?
|
| Malnutrition | 3 | 2022 | 156 | 1.120 |
Why?
|
| Antibodies, Protozoan | 14 | 2026 | 102 | 1.090 |
Why?
|
| Child | 72 | 2025 | 26086 | 1.090 |
Why?
|
| Measles Vaccine | 3 | 2022 | 12 | 1.090 |
Why?
|
| Mice | 81 | 2026 | 18219 | 1.080 |
Why?
|
| Trypanocidal Agents | 6 | 2026 | 33 | 1.080 |
Why?
|
| Anemia | 10 | 2020 | 351 | 1.070 |
Why?
|
| Molecular Sequence Data | 36 | 2014 | 3469 | 1.060 |
Why?
|
| Gene Expression | 20 | 2021 | 1486 | 1.060 |
Why?
|
| Europe | 9 | 2021 | 364 | 1.060 |
Why?
|
| Endemic Diseases | 10 | 2025 | 60 | 1.040 |
Why?
|
| Antinematodal Agents | 5 | 2019 | 11 | 1.030 |
Why?
|
| Zika Virus | 4 | 2019 | 151 | 1.010 |
Why?
|
| Research Personnel | 3 | 2021 | 142 | 1.000 |
Why?
|
| Antigens, Protozoan | 10 | 2026 | 77 | 1.000 |
Why?
|
| Malaria Vaccines | 3 | 2022 | 23 | 0.990 |
Why?
|
| Antibodies, Viral | 15 | 2025 | 1172 | 0.980 |
Why?
|
| Immunization | 9 | 2022 | 267 | 0.970 |
Why?
|
| Dengue | 5 | 2019 | 124 | 0.970 |
Why?
|
| Chronic Disease | 8 | 2019 | 1239 | 0.970 |
Why?
|
| Islam | 3 | 2018 | 11 | 0.960 |
Why?
|
| Schistosomiasis mansoni | 8 | 2023 | 24 | 0.960 |
Why?
|
| History, 20th Century | 11 | 2023 | 363 | 0.950 |
Why?
|
| China | 19 | 2019 | 278 | 0.940 |
Why?
|
| HIV Infections | 12 | 2020 | 2029 | 0.940 |
Why?
|
| Health Services Accessibility | 6 | 2020 | 693 | 0.940 |
Why?
|
| Goals | 4 | 2022 | 126 | 0.940 |
Why?
|
| Vaccines, Subunit | 9 | 2024 | 74 | 0.930 |
Why?
|
| Saccharomyces cerevisiae | 6 | 2023 | 398 | 0.920 |
Why?
|
| Nematoda | 3 | 2021 | 15 | 0.920 |
Why?
|
| Chagas Cardiomyopathy | 8 | 2021 | 46 | 0.910 |
Why?
|
| Research | 5 | 2021 | 264 | 0.900 |
Why?
|
| Adaptive Immunity | 3 | 2024 | 102 | 0.900 |
Why?
|
| Immunoglobulin G | 23 | 2026 | 793 | 0.900 |
Why?
|
| Leprosy | 4 | 2017 | 16 | 0.890 |
Why?
|
| Child, Preschool | 47 | 2025 | 14939 | 0.880 |
Why?
|
| Population Groups | 3 | 2019 | 31 | 0.880 |
Why?
|
| Severe Acute Respiratory Syndrome | 5 | 2020 | 39 | 0.860 |
Why?
|
| Recombinant Fusion Proteins | 11 | 2025 | 692 | 0.860 |
Why?
|
| Cytokines | 18 | 2026 | 1344 | 0.850 |
Why?
|
| Immunogenicity, Vaccine | 8 | 2024 | 126 | 0.840 |
Why?
|
| Cost-Benefit Analysis | 10 | 2024 | 547 | 0.840 |
Why?
|
| Tuberculosis | 7 | 2021 | 554 | 0.830 |
Why?
|
| Antigens, Viral | 2 | 2018 | 391 | 0.820 |
Why?
|
| Male | 105 | 2026 | 64435 | 0.810 |
Why?
|
| History, 21st Century | 10 | 2021 | 258 | 0.790 |
Why?
|
| Aluminum Hydroxide | 10 | 2026 | 41 | 0.790 |
Why?
|
| Africa South of the Sahara | 14 | 2021 | 120 | 0.790 |
Why?
|
| Career Choice | 1 | 2025 | 167 | 0.790 |
Why?
|
| Leishmaniasis, Cutaneous | 8 | 2020 | 50 | 0.780 |
Why?
|
| Wounds and Injuries | 6 | 2018 | 392 | 0.780 |
Why?
|
| Metalloendopeptidases | 8 | 2007 | 101 | 0.770 |
Why?
|
| Models, Animal | 2 | 2024 | 451 | 0.770 |
Why?
|
| Jews | 1 | 2023 | 33 | 0.760 |
Why?
|
| Americas | 9 | 2020 | 52 | 0.760 |
Why?
|
| Mebendazole | 4 | 2017 | 7 | 0.750 |
Why?
|
| Immunity, Innate | 3 | 2024 | 410 | 0.750 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2023 | 58 | 0.750 |
Why?
|
| Adolescent | 52 | 2026 | 20712 | 0.740 |
Why?
|
| Onchocerciasis | 7 | 2022 | 22 | 0.740 |
Why?
|
| Myocarditis | 2 | 2021 | 132 | 0.740 |
Why?
|
| Latin America | 10 | 2020 | 108 | 0.730 |
Why?
|
| Middle East | 7 | 2018 | 36 | 0.730 |
Why?
|
| Adult | 59 | 2026 | 31099 | 0.720 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2021 | 503 | 0.720 |
Why?
|
| Drug Design | 4 | 2020 | 162 | 0.710 |
Why?
|
| Aspartic Acid Endopeptidases | 7 | 2018 | 30 | 0.710 |
Why?
|
| Humanities | 1 | 2021 | 15 | 0.710 |
Why?
|
| Young Adult | 32 | 2026 | 9982 | 0.710 |
Why?
|
| Social Values | 1 | 2021 | 46 | 0.710 |
Why?
|
| Asia | 8 | 2018 | 125 | 0.710 |
Why?
|
| Sex Distribution | 10 | 2025 | 317 | 0.700 |
Why?
|
| Zebrafish | 1 | 2024 | 417 | 0.690 |
Why?
|
| Freedom | 1 | 2021 | 17 | 0.680 |
Why?
|
| Health Care Costs | 8 | 2025 | 406 | 0.680 |
Why?
|
| Preventive Health Services | 3 | 2017 | 58 | 0.670 |
Why?
|
| Political Systems | 1 | 2020 | 2 | 0.670 |
Why?
|
| Autoantigens | 1 | 2021 | 100 | 0.670 |
Why?
|
| Clinical Trials as Topic | 11 | 2020 | 1121 | 0.660 |
Why?
|
| Leishmaniasis Vaccines | 5 | 2020 | 20 | 0.660 |
Why?
|
| Health Systems Plans | 1 | 2020 | 1 | 0.650 |
Why?
|
| Schools, Public Health | 3 | 2006 | 5 | 0.650 |
Why?
|
| Treatment Refusal | 1 | 2021 | 80 | 0.650 |
Why?
|
| Sequence Alignment | 15 | 2017 | 583 | 0.640 |
Why?
|
| Global Warming | 1 | 2020 | 4 | 0.640 |
Why?
|
| National Health Programs | 2 | 2011 | 20 | 0.640 |
Why?
|
| Typhus, Epidemic Louse-Borne | 1 | 2020 | 1 | 0.640 |
Why?
|
| Travel | 3 | 2018 | 126 | 0.640 |
Why?
|
| Biomedical Technology | 1 | 2020 | 38 | 0.630 |
Why?
|
| Russia | 4 | 2021 | 38 | 0.630 |
Why?
|
| Nematode Infections | 2 | 2019 | 6 | 0.630 |
Why?
|
| Trust | 1 | 2021 | 88 | 0.630 |
Why?
|
| Infant | 33 | 2025 | 13224 | 0.630 |
Why?
|
| Social Determinants of Health | 2 | 2020 | 165 | 0.630 |
Why?
|
| Diffusion of Innovation | 2 | 2019 | 84 | 0.620 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 6783 | 0.620 |
Why?
|
| Computer Simulation | 8 | 2025 | 671 | 0.620 |
Why?
|
| Public Sector | 3 | 2016 | 17 | 0.620 |
Why?
|
| Noncommunicable Diseases | 2 | 2017 | 21 | 0.620 |
Why?
|
| Community Participation | 1 | 2020 | 42 | 0.620 |
Why?
|
| Licensure | 1 | 2019 | 14 | 0.600 |
Why?
|
| Influenza, Human | 2 | 2023 | 702 | 0.600 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 148 | 0.600 |
Why?
|
| Immunity | 3 | 2020 | 179 | 0.600 |
Why?
|
| Reproductive Health | 1 | 2019 | 48 | 0.590 |
Why?
|
| Schistosoma | 4 | 2024 | 13 | 0.590 |
Why?
|
| Th17 Cells | 1 | 2020 | 97 | 0.590 |
Why?
|
| Behavior Therapy | 1 | 2021 | 271 | 0.590 |
Why?
|
| Access to Information | 1 | 2019 | 46 | 0.580 |
Why?
|
| Age Distribution | 10 | 2025 | 421 | 0.580 |
Why?
|
| Risk Factors | 24 | 2025 | 10941 | 0.570 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 111 | 0.570 |
Why?
|
| Leadership | 2 | 2020 | 245 | 0.560 |
Why?
|
| Human Development | 1 | 2018 | 6 | 0.560 |
Why?
|
| Triatoma | 2 | 2015 | 35 | 0.560 |
Why?
|
| Rubella | 2 | 2025 | 18 | 0.560 |
Why?
|
| Armed Conflicts | 1 | 2018 | 7 | 0.550 |
Why?
|
| Sequence Homology, Amino Acid | 15 | 2014 | 623 | 0.550 |
Why?
|
| Milk Proteins | 1 | 2018 | 95 | 0.550 |
Why?
|
| Factor Xa Inhibitors | 4 | 2011 | 59 | 0.550 |
Why?
|
| DNA, Complementary | 11 | 2015 | 425 | 0.550 |
Why?
|
| Dermatology | 1 | 2018 | 30 | 0.550 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 2017 | 3 | 0.540 |
Why?
|
| Middle Aged | 43 | 2026 | 28371 | 0.540 |
Why?
|
| Educational Status | 2 | 2018 | 275 | 0.530 |
Why?
|
| Brazil | 13 | 2023 | 116 | 0.530 |
Why?
|
| Alphavirus Infections | 1 | 2017 | 12 | 0.530 |
Why?
|
| Alphavirus | 1 | 2017 | 17 | 0.530 |
Why?
|
| Antibody Formation | 6 | 2025 | 227 | 0.530 |
Why?
|
| Mass Vaccination | 3 | 2025 | 14 | 0.530 |
Why?
|
| Arboviruses | 1 | 2017 | 25 | 0.520 |
Why?
|
| Arthropod Vectors | 1 | 2017 | 18 | 0.520 |
Why?
|
| Alum Compounds | 8 | 2022 | 41 | 0.520 |
Why?
|
| Infant, Newborn | 20 | 2025 | 8513 | 0.520 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2016 | 22 | 0.520 |
Why?
|
| Editorial Policies | 2 | 2020 | 50 | 0.520 |
Why?
|
| Universities | 2 | 2015 | 127 | 0.510 |
Why?
|
| Human Activities | 2 | 2016 | 8 | 0.510 |
Why?
|
| Child Welfare | 3 | 2013 | 70 | 0.510 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2019 | 261 | 0.510 |
Why?
|
| Genetic Engineering | 1 | 2018 | 161 | 0.510 |
Why?
|
| Viral Envelope Proteins | 2 | 2020 | 154 | 0.510 |
Why?
|
| Research Support as Topic | 5 | 2017 | 61 | 0.510 |
Why?
|
| Hygiene Hypothesis | 1 | 2016 | 2 | 0.500 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 265 | 0.500 |
Why?
|
| Asia, Southeastern | 5 | 2020 | 22 | 0.500 |
Why?
|
| Ascaris suum | 4 | 2021 | 32 | 0.500 |
Why?
|
| Aged | 33 | 2025 | 20865 | 0.500 |
Why?
|
| Genome, Helminth | 2 | 2014 | 13 | 0.490 |
Why?
|
| Metalloproteases | 3 | 2007 | 14 | 0.490 |
Why?
|
| Cricetinae | 15 | 2012 | 361 | 0.490 |
Why?
|
| Disease Models, Animal | 24 | 2025 | 4666 | 0.480 |
Why?
|
| Onchocerca volvulus | 5 | 2019 | 16 | 0.480 |
Why?
|
| Religion | 1 | 2016 | 44 | 0.480 |
Why?
|
| Chemoprevention | 3 | 2019 | 49 | 0.480 |
Why?
|
| Mosquito Control | 1 | 2016 | 32 | 0.480 |
Why?
|
| Mosquito Vectors | 1 | 2016 | 34 | 0.470 |
Why?
|
| Toxoplasmosis | 4 | 2020 | 22 | 0.470 |
Why?
|
| Antiprotozoal Agents | 1 | 2016 | 41 | 0.470 |
Why?
|
| Texas | 14 | 2024 | 3642 | 0.470 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2008 | 20 | 0.470 |
Why?
|
| Onchocerciasis, Ocular | 3 | 2017 | 4 | 0.470 |
Why?
|
| Pharmaceutical Preparations | 2 | 2019 | 79 | 0.470 |
Why?
|
| Saccharomycetales | 5 | 2021 | 36 | 0.460 |
Why?
|
| Enterobiasis | 1 | 2015 | 4 | 0.460 |
Why?
|
| Acute Disease | 3 | 2018 | 1147 | 0.460 |
Why?
|
| Decision Making | 1 | 2021 | 711 | 0.450 |
Why?
|
| Aedes | 1 | 2016 | 103 | 0.450 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2025 | 28 | 0.450 |
Why?
|
| Insect Bites and Stings | 1 | 2015 | 41 | 0.450 |
Why?
|
| Parasites | 3 | 2024 | 33 | 0.440 |
Why?
|
| Child Health | 3 | 2024 | 68 | 0.440 |
Why?
|
| Drug Discovery | 2 | 2015 | 179 | 0.440 |
Why?
|
| Geography | 8 | 2020 | 114 | 0.430 |
Why?
|
| Asthma | 3 | 2016 | 921 | 0.430 |
Why?
|
| Central Nervous System Infections | 1 | 2014 | 21 | 0.430 |
Why?
|
| Pulse Therapy, Drug | 1 | 2014 | 10 | 0.420 |
Why?
|
| Parasite Load | 7 | 2018 | 31 | 0.420 |
Why?
|
| Microcephaly | 2 | 2017 | 348 | 0.420 |
Why?
|
| Encephalitis, St. Louis | 1 | 2014 | 24 | 0.420 |
Why?
|
| Skin Diseases, Infectious | 1 | 2014 | 25 | 0.420 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2022 | 464 | 0.420 |
Why?
|
| Immunity, Cellular | 7 | 2022 | 194 | 0.420 |
Why?
|
| Registries | 2 | 2020 | 1607 | 0.410 |
Why?
|
| Child Mortality | 3 | 2019 | 22 | 0.410 |
Why?
|
| North America | 4 | 2018 | 256 | 0.410 |
Why?
|
| Seroepidemiologic Studies | 8 | 2021 | 167 | 0.410 |
Why?
|
| Biliary Tract Diseases | 1 | 2013 | 32 | 0.410 |
Why?
|
| Chikungunya Fever | 1 | 2014 | 35 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2567 | 0.410 |
Why?
|
| Protein Domains | 8 | 2025 | 252 | 0.400 |
Why?
|
| Infection Control | 3 | 2020 | 162 | 0.400 |
Why?
|
| Incidence | 15 | 2022 | 3313 | 0.400 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 510 | 0.400 |
Why?
|
| Parasite Egg Count | 13 | 2020 | 28 | 0.400 |
Why?
|
| Thiazoles | 1 | 2014 | 112 | 0.400 |
Why?
|
| Cysteine Endopeptidases | 5 | 2024 | 110 | 0.400 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 395 | 0.390 |
Why?
|
| Ecosystem | 4 | 2023 | 90 | 0.390 |
Why?
|
| Pregnancy | 17 | 2024 | 7392 | 0.390 |
Why?
|
| Hypertension | 2 | 2019 | 1347 | 0.390 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 205 | 0.380 |
Why?
|
| Dog Diseases | 4 | 2020 | 59 | 0.380 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 265 | 0.380 |
Why?
|
| Toxocara canis | 3 | 2020 | 8 | 0.380 |
Why?
|
| Plague | 1 | 2012 | 3 | 0.370 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 18 | 0.370 |
Why?
|
| Rural Population | 6 | 2017 | 272 | 0.370 |
Why?
|
| Mesocricetus | 8 | 2011 | 65 | 0.370 |
Why?
|
| Echinococcosis | 2 | 2002 | 6 | 0.370 |
Why?
|
| Starvation | 1 | 2012 | 17 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 706 | 0.370 |
Why?
|
| Metabolome | 2 | 2021 | 324 | 0.370 |
Why?
|
| Aspartic Acid Proteases | 4 | 2019 | 9 | 0.370 |
Why?
|
| Immunotherapy | 4 | 2026 | 759 | 0.370 |
Why?
|
| Physicians | 1 | 2019 | 635 | 0.370 |
Why?
|
| Biotechnology | 6 | 2015 | 59 | 0.370 |
Why?
|
| Vaccines, Inactivated | 3 | 2021 | 149 | 0.360 |
Why?
|
| Rabies | 4 | 2019 | 12 | 0.360 |
Why?
|
| Base Sequence | 11 | 2007 | 2734 | 0.360 |
Why?
|
| Lipid A | 5 | 2022 | 23 | 0.360 |
Why?
|
| Leishmania | 2 | 2023 | 34 | 0.350 |
Why?
|
| Larva Migrans | 5 | 2016 | 6 | 0.350 |
Why?
|
| Religion and Medicine | 1 | 2011 | 26 | 0.350 |
Why?
|
| Organizations, Nonprofit | 2 | 2015 | 27 | 0.350 |
Why?
|
| Immune Sera | 5 | 2004 | 54 | 0.350 |
Why?
|
| Death | 1 | 2012 | 76 | 0.350 |
Why?
|
| Heart | 6 | 2023 | 659 | 0.350 |
Why?
|
| Esophagus | 2 | 2011 | 231 | 0.340 |
Why?
|
| Cysticercosis | 4 | 2014 | 21 | 0.340 |
Why?
|
| Hypersensitivity | 4 | 2018 | 227 | 0.340 |
Why?
|
| Schools, Medical | 2 | 2010 | 116 | 0.340 |
Why?
|
| Germany | 2 | 2021 | 59 | 0.340 |
Why?
|
| Markov Chains | 3 | 2024 | 101 | 0.340 |
Why?
|
| Retinol-Binding Proteins | 2 | 2018 | 21 | 0.340 |
Why?
|
| Inflammation | 4 | 2022 | 1483 | 0.340 |
Why?
|
| Salivary Proteins and Peptides | 3 | 2020 | 18 | 0.330 |
Why?
|
| Molecular Weight | 12 | 2020 | 277 | 0.330 |
Why?
|
| Economic Development | 2 | 2022 | 4 | 0.330 |
Why?
|
| Immunodominant Epitopes | 2 | 2015 | 46 | 0.330 |
Why?
|
| Disease Vectors | 3 | 2020 | 22 | 0.330 |
Why?
|
| Mice, Inbred AKR | 2 | 2022 | 15 | 0.330 |
Why?
|
| Urban Population | 3 | 2020 | 282 | 0.330 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 409 | 0.320 |
Why?
|
| Host-Parasite Interactions | 9 | 2020 | 71 | 0.320 |
Why?
|
| Nuclear Weapons | 1 | 2010 | 1 | 0.320 |
Why?
|
| Public Opinion | 2 | 2021 | 63 | 0.320 |
Why?
|
| Phlebotomus | 2 | 2020 | 14 | 0.320 |
Why?
|
| Tetraspanins | 4 | 2016 | 30 | 0.320 |
Why?
|
| Poverty Areas | 3 | 2018 | 36 | 0.310 |
Why?
|
| India | 4 | 2021 | 233 | 0.310 |
Why?
|
| Feces | 13 | 2025 | 720 | 0.310 |
Why?
|
| Elephantiasis, Filarial | 4 | 2018 | 12 | 0.310 |
Why?
|
| Th1 Cells | 6 | 2022 | 159 | 0.310 |
Why?
|
| Hemoglobins | 7 | 2009 | 286 | 0.310 |
Why?
|
| Models, Economic | 3 | 2021 | 59 | 0.310 |
Why?
|
| Ivermectin | 2 | 2022 | 8 | 0.310 |
Why?
|
| Anticoagulants | 2 | 2011 | 601 | 0.310 |
Why?
|
| Reproductive Medicine | 1 | 2009 | 19 | 0.310 |
Why?
|
| Heme | 1 | 2010 | 46 | 0.310 |
Why?
|
| Liver Diseases | 1 | 2013 | 379 | 0.300 |
Why?
|
| Antimalarials | 2 | 2009 | 40 | 0.300 |
Why?
|
| Vaccines, DNA | 2 | 2022 | 44 | 0.300 |
Why?
|
| Pakistan | 2 | 2020 | 99 | 0.300 |
Why?
|
| Life Cycle Stages | 5 | 2020 | 25 | 0.300 |
Why?
|
| Female Urogenital Diseases | 1 | 2009 | 8 | 0.300 |
Why?
|
| History, 19th Century | 3 | 2021 | 110 | 0.300 |
Why?
|
| Pediatrics | 1 | 2019 | 1239 | 0.300 |
Why?
|
| Drugs, Essential | 1 | 2009 | 7 | 0.300 |
Why?
|
| Peptides | 4 | 2011 | 704 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 915 | 0.290 |
Why?
|
| Carrier Proteins | 2 | 2005 | 1000 | 0.290 |
Why?
|
| Cats | 4 | 2020 | 115 | 0.290 |
Why?
|
| Oxidative Stress | 1 | 2013 | 795 | 0.290 |
Why?
|
| Filariasis | 3 | 2018 | 28 | 0.290 |
Why?
|
| Lung | 10 | 2025 | 1533 | 0.290 |
Why?
|
| Interferon-gamma | 7 | 2019 | 550 | 0.280 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2022 | 141 | 0.280 |
Why?
|
| Technology, Pharmaceutical | 4 | 2017 | 19 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2025 | 785 | 0.280 |
Why?
|
| Sex Factors | 9 | 2021 | 1338 | 0.280 |
Why?
|
| Technology Transfer | 3 | 2020 | 8 | 0.280 |
Why?
|
| Phospholipids | 2 | 2020 | 99 | 0.280 |
Why?
|
| Skin | 6 | 2012 | 536 | 0.280 |
Why?
|
| Prejudice | 1 | 2008 | 39 | 0.280 |
Why?
|
| Antigenic Variation | 2 | 2021 | 37 | 0.270 |
Why?
|
| Peptide Hydrolases | 7 | 2022 | 130 | 0.270 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 130 | 0.270 |
Why?
|
| Health Status Disparities | 3 | 2020 | 276 | 0.270 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2024 | 122 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 502 | 0.270 |
Why?
|
| Forecasting | 2 | 2020 | 349 | 0.260 |
Why?
|
| Sanitation | 3 | 2017 | 16 | 0.260 |
Why?
|
| Policy Making | 4 | 2020 | 60 | 0.260 |
Why?
|
| Mediterranean Region | 2 | 2018 | 8 | 0.260 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 1996 | 38 | 0.260 |
Why?
|
| Double-Blind Method | 5 | 2026 | 1620 | 0.260 |
Why?
|
| Antigen-Presenting Cells | 1 | 2008 | 123 | 0.260 |
Why?
|
| Genes, Helminth | 4 | 2003 | 19 | 0.260 |
Why?
|
| Brugia malayi | 2 | 2018 | 40 | 0.260 |
Why?
|
| Epitopes | 7 | 2024 | 321 | 0.260 |
Why?
|
| Morbidity | 4 | 2018 | 257 | 0.250 |
Why?
|
| Schistosoma mansoni | 6 | 2023 | 24 | 0.250 |
Why?
|
| Macaca mulatta | 4 | 2021 | 492 | 0.250 |
Why?
|
| Financial Management | 2 | 2020 | 12 | 0.250 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2004 | 135 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2018 | 353 | 0.250 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 2099 | 0.250 |
Why?
|
| Superantigens | 2 | 2017 | 20 | 0.250 |
Why?
|
| Venezuela | 4 | 2019 | 14 | 0.250 |
Why?
|
| N-Glycosyl Hydrolases | 2 | 2016 | 13 | 0.250 |
Why?
|
| Mental Disorders | 1 | 2014 | 903 | 0.250 |
Why?
|
| United Kingdom | 2 | 2017 | 257 | 0.240 |
Why?
|
| Nigeria | 2 | 2019 | 71 | 0.240 |
Why?
|
| Th2 Cells | 6 | 2021 | 188 | 0.240 |
Why?
|
| Delivery of Health Care | 5 | 2019 | 683 | 0.240 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2021 | 966 | 0.240 |
Why?
|
| Cysteine | 2 | 2017 | 137 | 0.240 |
Why?
|
| Leishmania donovani | 2 | 2016 | 26 | 0.240 |
Why?
|
| Blood Donors | 3 | 2014 | 58 | 0.240 |
Why?
|
| Budgets | 1 | 2006 | 15 | 0.240 |
Why?
|
| Orphan Drug Production | 1 | 2006 | 4 | 0.240 |
Why?
|
| HIV | 2 | 2019 | 174 | 0.240 |
Why?
|
| Technology | 2 | 2024 | 68 | 0.240 |
Why?
|
| Coinfection | 2 | 2020 | 185 | 0.240 |
Why?
|
| Hemeproteins | 1 | 2005 | 8 | 0.230 |
Why?
|
| Gene Library | 3 | 2004 | 211 | 0.230 |
Why?
|
| Transduction, Genetic | 2 | 2024 | 277 | 0.230 |
Why?
|
| Molecular Mimicry | 2 | 2021 | 16 | 0.230 |
Why?
|
| Immunity, Mucosal | 2 | 2025 | 97 | 0.230 |
Why?
|
| Residence Characteristics | 3 | 2017 | 291 | 0.230 |
Why?
|
| Vaccines, Combined | 4 | 2023 | 40 | 0.230 |
Why?
|
| Biomarkers | 6 | 2025 | 3382 | 0.220 |
Why?
|
| Rural Health | 4 | 2006 | 46 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2020 | 518 | 0.220 |
Why?
|
| DNA, Helminth | 5 | 2010 | 23 | 0.220 |
Why?
|
| Genetic Vectors | 5 | 2024 | 897 | 0.220 |
Why?
|
| Immunologic Memory | 2 | 2018 | 197 | 0.210 |
Why?
|
| Immunoglobulin E | 5 | 2018 | 215 | 0.210 |
Why?
|
| Rare Diseases | 1 | 2006 | 205 | 0.210 |
Why?
|
| Central Nervous System Diseases | 3 | 1993 | 98 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2022 | 877 | 0.210 |
Why?
|
| Democracy | 1 | 2024 | 2 | 0.210 |
Why?
|
| Neutralization Tests | 2 | 2024 | 226 | 0.210 |
Why?
|
| Containment of Biohazards | 1 | 2024 | 4 | 0.210 |
Why?
|
| Cholera | 3 | 2021 | 39 | 0.210 |
Why?
|
| Drug Industry | 3 | 2015 | 48 | 0.210 |
Why?
|
| Mucous Membrane | 2 | 2022 | 93 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2008 | 1206 | 0.210 |
Why?
|
| Africa, Northern | 2 | 2015 | 10 | 0.210 |
Why?
|
| Virology | 1 | 2024 | 31 | 0.200 |
Why?
|
| Injections, Intramuscular | 4 | 2024 | 185 | 0.200 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 269 | 0.200 |
Why?
|
| Education, Medical | 2 | 2008 | 292 | 0.200 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 1994 | 28 | 0.200 |
Why?
|
| Medical Laboratory Science | 1 | 2003 | 12 | 0.200 |
Why?
|
| Kwashiorkor | 1 | 2023 | 21 | 0.200 |
Why?
|
| Insect Proteins | 2 | 2020 | 96 | 0.200 |
Why?
|
| Models, Theoretical | 3 | 2017 | 361 | 0.190 |
Why?
|
| National Socialism | 1 | 2023 | 4 | 0.190 |
Why?
|
| Cricetulus | 2 | 2025 | 89 | 0.190 |
Why?
|
| Lymphocyte Activation | 1 | 2005 | 633 | 0.190 |
Why?
|
| Trichinella spiralis | 1 | 2003 | 22 | 0.190 |
Why?
|
| CHO Cells | 2 | 2025 | 151 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2019 | 482 | 0.190 |
Why?
|
| Emigration and Immigration | 2 | 2018 | 80 | 0.190 |
Why?
|
| Postpartum Period | 1 | 2024 | 238 | 0.190 |
Why?
|
| Gabon | 4 | 2024 | 8 | 0.190 |
Why?
|
| Immunoglobulin M | 3 | 2018 | 212 | 0.180 |
Why?
|
| Anti-HIV Agents | 1 | 2006 | 347 | 0.180 |
Why?
|
| Crystallography, X-Ray | 3 | 2010 | 364 | 0.180 |
Why?
|
| Laboratories | 1 | 2003 | 79 | 0.180 |
Why?
|
| Phylogeny | 5 | 2020 | 687 | 0.180 |
Why?
|
| Eosinophils | 2 | 2020 | 120 | 0.180 |
Why?
|
| Fermentation | 3 | 2020 | 66 | 0.180 |
Why?
|
| Vietnam | 1 | 2022 | 63 | 0.180 |
Why?
|
| Blood Coagulation | 4 | 2011 | 134 | 0.180 |
Why?
|
| Protein Structure, Tertiary | 3 | 2021 | 715 | 0.180 |
Why?
|
| Glucosides | 2 | 2019 | 54 | 0.180 |
Why?
|
| Organizations | 1 | 2021 | 17 | 0.180 |
Why?
|
| RNA, Protozoan | 1 | 2021 | 10 | 0.180 |
Why?
|
| Intestinal Volvulus | 1 | 2022 | 41 | 0.180 |
Why?
|
| Hepatitis C | 2 | 2017 | 376 | 0.170 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 1712 | 0.170 |
Why?
|
| France | 1 | 2021 | 90 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 144 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2017 | 141 | 0.170 |
Why?
|
| Time Factors | 6 | 2021 | 6196 | 0.170 |
Why?
|
| Variant Surface Glycoproteins, Trypanosoma | 2 | 2018 | 6 | 0.170 |
Why?
|
| Political Activism | 1 | 2021 | 3 | 0.170 |
Why?
|
| Protein Conformation | 6 | 2019 | 731 | 0.170 |
Why?
|
| Opisthorchiasis | 2 | 2011 | 2 | 0.170 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 222 | 0.170 |
Why?
|
| USSR | 1 | 2021 | 4 | 0.170 |
Why?
|
| Poliomyelitis | 2 | 2025 | 17 | 0.170 |
Why?
|
| Population Surveillance | 4 | 2019 | 393 | 0.170 |
Why?
|
| Rats | 8 | 2014 | 3371 | 0.170 |
Why?
|
| Disease Management | 2 | 2017 | 555 | 0.170 |
Why?
|
| History, 18th Century | 1 | 2021 | 68 | 0.170 |
Why?
|
| Dissent and Disputes | 1 | 2021 | 31 | 0.170 |
Why?
|
| Ethnic Violence | 1 | 2020 | 1 | 0.170 |
Why?
|
| Mortality, Premature | 2 | 2018 | 14 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 208 | 0.170 |
Why?
|
| Population Density | 1 | 2020 | 31 | 0.170 |
Why?
|
| Indians, South American | 1 | 2020 | 10 | 0.170 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2021 | 29 | 0.170 |
Why?
|
| Weather | 1 | 2020 | 16 | 0.170 |
Why?
|
| Genome | 2 | 2003 | 453 | 0.160 |
Why?
|
| HIV-1 | 1 | 2024 | 492 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2024 | 2551 | 0.160 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2020 | 13 | 0.160 |
Why?
|
| Cross Protection | 1 | 2020 | 10 | 0.160 |
Why?
|
| Cluster Analysis | 1 | 2022 | 412 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2020 | 44 | 0.160 |
Why?
|
| Health Status | 2 | 2012 | 371 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 8 | 2025 | 4714 | 0.160 |
Why?
|
| Maternal Health | 1 | 2020 | 29 | 0.160 |
Why?
|
| Prisons | 1 | 2020 | 15 | 0.160 |
Why?
|
| Strongylida Infections | 2 | 2018 | 14 | 0.160 |
Why?
|
| Health Resources | 1 | 2021 | 127 | 0.160 |
Why?
|
| Open Access Publishing | 1 | 2020 | 3 | 0.160 |
Why?
|
| Psychodidae | 2 | 2017 | 14 | 0.160 |
Why?
|
| Cat Diseases | 1 | 2020 | 15 | 0.160 |
Why?
|
| Ultraviolet Rays | 2 | 2019 | 191 | 0.160 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 15 | 0.160 |
Why?
|
| Monkey Diseases | 1 | 2020 | 17 | 0.160 |
Why?
|
| Interleukin-17 | 1 | 2021 | 125 | 0.160 |
Why?
|
| Fatty Acids | 1 | 2003 | 373 | 0.160 |
Why?
|
| Mexico | 3 | 2020 | 190 | 0.160 |
Why?
|
| Intention | 1 | 2021 | 101 | 0.160 |
Why?
|
| Africa, Southern | 1 | 2019 | 6 | 0.160 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2025 | 408 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 723 | 0.160 |
Why?
|
| Haiti | 2 | 2017 | 12 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 137 | 0.160 |
Why?
|
| Prisoners | 1 | 2020 | 38 | 0.160 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2019 | 21 | 0.150 |
Why?
|
| Economic Recession | 1 | 2019 | 2 | 0.150 |
Why?
|
| Pepsin A | 1 | 2019 | 11 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2019 | 40 | 0.150 |
Why?
|
| Congo | 1 | 2019 | 2 | 0.150 |
Why?
|
| Lymphokines | 1 | 2019 | 61 | 0.150 |
Why?
|
| Colombia | 1 | 2019 | 50 | 0.150 |
Why?
|
| Scabies | 1 | 2019 | 1 | 0.150 |
Why?
|
| Computational Biology | 2 | 2022 | 862 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 322 | 0.150 |
Why?
|
| Egypt | 2 | 2016 | 30 | 0.150 |
Why?
|
| Fluorometry | 2 | 2017 | 27 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 228 | 0.150 |
Why?
|
| Cholangiocarcinoma | 2 | 2011 | 125 | 0.150 |
Why?
|
| Intestines | 5 | 2017 | 587 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2008 | 1104 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 5 | 2020 | 1456 | 0.150 |
Why?
|
| Calcium Carbonate | 1 | 2019 | 11 | 0.150 |
Why?
|
| Mast Cells | 1 | 1999 | 67 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 2 | 2011 | 134 | 0.150 |
Why?
|
| Mississippi | 2 | 2024 | 35 | 0.150 |
Why?
|
| B-Lymphocytes | 5 | 2025 | 511 | 0.150 |
Why?
|
| Cytochrome-c Peroxidase | 1 | 1999 | 1 | 0.150 |
Why?
|
| Kenya | 1 | 2019 | 60 | 0.150 |
Why?
|
| Ghana | 1 | 2019 | 21 | 0.150 |
Why?
|
| Escherichia coli | 8 | 2024 | 991 | 0.150 |
Why?
|
| Candidemia | 1 | 2019 | 43 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 49 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2017 | 1482 | 0.140 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2019 | 95 | 0.140 |
Why?
|
| Antibodies, Catalytic | 1 | 2018 | 7 | 0.140 |
Why?
|
| Erythrocytes | 2 | 2018 | 187 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 1999 | 72 | 0.140 |
Why?
|
| Role | 1 | 2018 | 27 | 0.140 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2019 | 98 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2020 | 154 | 0.140 |
Why?
|
| Mutant Proteins | 2 | 2016 | 112 | 0.140 |
Why?
|
| Protective Agents | 1 | 2018 | 34 | 0.140 |
Why?
|
| Gram-Negative Bacteria | 1 | 1999 | 75 | 0.140 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2018 | 37 | 0.140 |
Why?
|
| Health Services | 1 | 2018 | 69 | 0.140 |
Why?
|
| Nippostrongylus | 1 | 2018 | 3 | 0.140 |
Why?
|
| Caribbean Region | 2 | 2008 | 19 | 0.140 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 56 | 0.140 |
Why?
|
| South America | 2 | 2020 | 45 | 0.140 |
Why?
|
| Models, Molecular | 4 | 2016 | 1059 | 0.140 |
Why?
|
| Blotting, Western | 4 | 2015 | 1016 | 0.140 |
Why?
|
| Open Reading Frames | 2 | 2010 | 198 | 0.140 |
Why?
|
| Schistosomiasis japonica | 1 | 1998 | 3 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2020 | 410 | 0.140 |
Why?
|
| Human Migration | 1 | 2018 | 12 | 0.140 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1999 | 98 | 0.140 |
Why?
|
| Schistosoma japonicum | 1 | 1998 | 8 | 0.140 |
Why?
|
| Farmers | 1 | 2018 | 13 | 0.140 |
Why?
|
| HLA-A Antigens | 1 | 2018 | 33 | 0.140 |
Why?
|
| Drug Costs | 2 | 2010 | 62 | 0.140 |
Why?
|
| HLA-B Antigens | 1 | 2018 | 30 | 0.140 |
Why?
|
| Dientamoebiasis | 2 | 2015 | 3 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 351 | 0.130 |
Why?
|
| Bacteremia | 2 | 1999 | 429 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 890 | 0.130 |
Why?
|
| Granuloma | 1 | 1998 | 60 | 0.130 |
Why?
|
| Myocardium | 2 | 2019 | 857 | 0.130 |
Why?
|
| Topography, Medical | 1 | 2017 | 6 | 0.130 |
Why?
|
| Membrane Proteins | 3 | 2024 | 1591 | 0.130 |
Why?
|
| X-Ray Diffraction | 2 | 2010 | 99 | 0.130 |
Why?
|
| Microbiota | 1 | 2023 | 438 | 0.130 |
Why?
|
| Ascaris lumbricoides | 3 | 2014 | 20 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2017 | 3672 | 0.130 |
Why?
|
| Disease Reservoirs | 3 | 2014 | 38 | 0.130 |
Why?
|
| Parasitemia | 4 | 2019 | 25 | 0.130 |
Why?
|
| Cryptosporidiosis | 2 | 2015 | 35 | 0.130 |
Why?
|
| Vaccines, Attenuated | 1 | 1998 | 173 | 0.130 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 8 | 0.130 |
Why?
|
| Health Care Sector | 1 | 2017 | 19 | 0.130 |
Why?
|
| District of Columbia | 2 | 2010 | 16 | 0.130 |
Why?
|
| Mice, SCID | 1 | 2018 | 585 | 0.130 |
Why?
|
| Antigens, Surface | 4 | 2007 | 112 | 0.130 |
Why?
|
| Autistic Disorder | 1 | 2021 | 395 | 0.130 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2017 | 8 | 0.130 |
Why?
|
| Personal Autonomy | 1 | 2018 | 209 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 1595 | 0.130 |
Why?
|
| Developed Countries | 2 | 2015 | 44 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 452 | 0.130 |
Why?
|
| South Sudan | 1 | 2016 | 1 | 0.130 |
Why?
|
| Refugee Camps | 1 | 2016 | 2 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 612 | 0.120 |
Why?
|
| Music | 1 | 2016 | 17 | 0.120 |
Why?
|
| Comorbidity | 4 | 2019 | 1582 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2017 | 148 | 0.120 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 397 | 0.120 |
Why?
|
| Oceans and Seas | 1 | 2016 | 8 | 0.120 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 395 | 0.120 |
Why?
|
| Drug Evaluation | 1 | 2016 | 101 | 0.120 |
Why?
|
| Transients and Migrants | 1 | 2016 | 31 | 0.120 |
Why?
|
| Education | 1 | 2016 | 112 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2017 | 170 | 0.120 |
Why?
|
| Pericarditis | 1 | 2016 | 43 | 0.120 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 150 | 0.120 |
Why?
|
| Age Factors | 7 | 2012 | 2826 | 0.120 |
Why?
|
| Writing | 1 | 2016 | 59 | 0.120 |
Why?
|
| Public Health Administration | 2 | 2019 | 9 | 0.120 |
Why?
|
| Iatrogenic Disease | 1 | 2016 | 118 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2014 | 687 | 0.120 |
Why?
|
| Immunity, Herd | 2 | 2025 | 14 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 360 | 0.120 |
Why?
|
| Health Transition | 1 | 2015 | 9 | 0.120 |
Why?
|
| Refugees | 1 | 2016 | 41 | 0.120 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2015 | 16 | 0.120 |
Why?
|
| Species Specificity | 5 | 2014 | 474 | 0.110 |
Why?
|
| Mutagenesis | 1 | 2016 | 325 | 0.110 |
Why?
|
| Consensus | 1 | 2018 | 528 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 200 | 0.110 |
Why?
|
| Interleukin-4 | 3 | 2022 | 145 | 0.110 |
Why?
|
| Cell Proliferation | 6 | 2018 | 2464 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2015 | 124 | 0.110 |
Why?
|
| Dysentery, Amebic | 1 | 2015 | 1 | 0.110 |
Why?
|
| Blastocystis Infections | 1 | 2015 | 5 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 337 | 0.110 |
Why?
|
| Plasmodium falciparum | 4 | 2021 | 81 | 0.110 |
Why?
|
| Aging | 1 | 2002 | 1242 | 0.110 |
Why?
|
| Family Characteristics | 2 | 2013 | 97 | 0.110 |
Why?
|
| Life Tables | 1 | 2014 | 24 | 0.110 |
Why?
|
| Aluminum Compounds | 2 | 2012 | 16 | 0.110 |
Why?
|
| Health Services Needs and Demand | 3 | 2017 | 171 | 0.110 |
Why?
|
| Nephritis, Interstitial | 1 | 2015 | 41 | 0.110 |
Why?
|
| Anisakis | 1 | 1994 | 1 | 0.110 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 81 | 0.110 |
Why?
|
| Anisakiasis | 1 | 1994 | 2 | 0.110 |
Why?
|
| Fibrosis | 3 | 2022 | 418 | 0.110 |
Why?
|
| Cnidarian Venoms | 1 | 2014 | 10 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 239 | 0.110 |
Why?
|
| Skin Diseases, Viral | 1 | 2014 | 3 | 0.110 |
Why?
|
| Skin Diseases, Parasitic | 1 | 2014 | 4 | 0.110 |
Why?
|
| Central America | 1 | 2014 | 21 | 0.110 |
Why?
|
| Chromatography, Gel | 4 | 2016 | 64 | 0.110 |
Why?
|
| Southeastern United States | 1 | 2014 | 35 | 0.110 |
Why?
|
| Nitro Compounds | 1 | 2014 | 22 | 0.100 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2014 | 38 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 2333 | 0.100 |
Why?
|
| Australasia | 1 | 2014 | 5 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 1362 | 0.100 |
Why?
|
| Opisthorchis | 2 | 2011 | 2 | 0.100 |
Why?
|
| Indonesia | 1 | 2014 | 21 | 0.100 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1995 | 158 | 0.100 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2014 | 22 | 0.100 |
Why?
|
| Capital Financing | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hydroxybutyrates | 1 | 2013 | 31 | 0.100 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 84 | 0.100 |
Why?
|
| Kinetics | 5 | 2009 | 1084 | 0.100 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2013 | 49 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2024 | 235 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 256 | 0.100 |
Why?
|
| Malaria, Falciparum | 2 | 2021 | 58 | 0.100 |
Why?
|
| Drug Resistance, Microbial | 1 | 2014 | 195 | 0.100 |
Why?
|
| Democratic Republic of the Congo | 1 | 2013 | 18 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 1270 | 0.100 |
Why?
|
| Larva Migrans, Visceral | 1 | 1993 | 1 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2011 | 103 | 0.100 |
Why?
|
| Data Mining | 1 | 2014 | 66 | 0.100 |
Why?
|
| Greece | 1 | 2013 | 12 | 0.100 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2013 | 17 | 0.100 |
Why?
|
| Oceania | 1 | 2013 | 4 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2019 | 1342 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2013 | 68 | 0.100 |
Why?
|
| Absenteeism | 1 | 2013 | 20 | 0.100 |
Why?
|
| Protein Stability | 3 | 2020 | 165 | 0.100 |
Why?
|
| Insulin, Regular, Human | 2 | 2022 | 12 | 0.100 |
Why?
|
| Insect Control | 2 | 2016 | 11 | 0.100 |
Why?
|
| Strongyloidiasis | 1 | 1993 | 51 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 238 | 0.100 |
Why?
|
| Viscera | 1 | 2013 | 56 | 0.100 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 82 | 0.090 |
Why?
|
| Hypertrophy | 1 | 2013 | 99 | 0.090 |
Why?
|
| Helminthiasis, Animal | 2 | 2010 | 2 | 0.090 |
Why?
|
| Metagenomics | 1 | 2014 | 114 | 0.090 |
Why?
|
| Honduras | 2 | 2025 | 25 | 0.090 |
Why?
|
| Child Health Services | 1 | 2013 | 86 | 0.090 |
Why?
|
| Histamine Release | 1 | 2012 | 10 | 0.090 |
Why?
|
| Basophils | 1 | 2012 | 11 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2012 | 254 | 0.090 |
Why?
|
| Schools | 3 | 2019 | 235 | 0.090 |
Why?
|
| Academies and Institutes | 1 | 2013 | 81 | 0.090 |
Why?
|
| Ligands | 2 | 2005 | 482 | 0.090 |
Why?
|
| Efficiency | 1 | 2013 | 74 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2014 | 338 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2018 | 3829 | 0.090 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 611 | 0.090 |
Why?
|
| Emulsions | 2 | 2002 | 69 | 0.090 |
Why?
|
| Phosphates | 1 | 2012 | 111 | 0.090 |
Why?
|
| Urticaria | 1 | 2012 | 19 | 0.090 |
Why?
|
| CD13 Antigens | 1 | 2012 | 10 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 323 | 0.090 |
Why?
|
| Haemonchus | 3 | 2008 | 3 | 0.090 |
Why?
|
| Biological Availability | 2 | 2002 | 137 | 0.090 |
Why?
|
| Soybean Oil | 2 | 2002 | 71 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2012 | 319 | 0.090 |
Why?
|
| Plasmodium vivax | 1 | 2012 | 21 | 0.090 |
Why?
|
| Asia, Central | 1 | 2011 | 2 | 0.090 |
Why?
|
| Alabama | 2 | 2024 | 44 | 0.090 |
Why?
|
| United States Agency for International Development | 1 | 2011 | 1 | 0.090 |
Why?
|
| Genomics | 2 | 2011 | 1618 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2014 | 194 | 0.090 |
Why?
|
| Glycomics | 1 | 2011 | 15 | 0.090 |
Why?
|
| Catholicism | 1 | 2011 | 6 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2020 | 12823 | 0.090 |
Why?
|
| Military Personnel | 1 | 2013 | 210 | 0.080 |
Why?
|
| Temperature | 3 | 2017 | 289 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2025 | 2088 | 0.080 |
Why?
|
| Antibodies | 2 | 2012 | 320 | 0.080 |
Why?
|
| Rabies Vaccines | 1 | 2010 | 12 | 0.080 |
Why?
|
| Cholera Vaccines | 1 | 2010 | 8 | 0.080 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 1990 | 3 | 0.080 |
Why?
|
| Drug Stability | 3 | 2017 | 56 | 0.080 |
Why?
|
| Cells, Cultured | 4 | 2014 | 2894 | 0.080 |
Why?
|
| Immunization, Passive | 2 | 2022 | 122 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 131 | 0.080 |
Why?
|
| Rainforest | 2 | 2020 | 3 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2013 | 192 | 0.080 |
Why?
|
| Connective Tissue | 2 | 2006 | 26 | 0.080 |
Why?
|
| Disease Progression | 3 | 2023 | 2193 | 0.080 |
Why?
|
| Paramyxoviridae Infections | 1 | 1990 | 49 | 0.080 |
Why?
|
| Students, Public Health | 1 | 2010 | 4 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1015 | 0.080 |
Why?
|
| Arctic Regions | 1 | 2010 | 5 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 763 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 3795 | 0.080 |
Why?
|
| Elephantiasis | 1 | 2010 | 3 | 0.080 |
Why?
|
| Hepatitis B Vaccines | 2 | 2022 | 49 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2014 | 1223 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 92 | 0.080 |
Why?
|
| Protease Inhibitors | 2 | 2007 | 93 | 0.080 |
Why?
|
| Plasmodium berghei | 2 | 2012 | 13 | 0.080 |
Why?
|
| Parenting | 1 | 2013 | 347 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2011 | 827 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2021 | 126 | 0.070 |
Why?
|
| Pest Control | 1 | 2009 | 7 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 3 | 2020 | 92 | 0.070 |
Why?
|
| Geography, Medical | 2 | 2019 | 16 | 0.070 |
Why?
|
| Bedding and Linens | 1 | 2009 | 8 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 407 | 0.070 |
Why?
|
| Insulin | 3 | 2022 | 1140 | 0.070 |
Why?
|
| West Indies | 1 | 2008 | 6 | 0.070 |
Why?
|
| Foundations | 1 | 2008 | 24 | 0.070 |
Why?
|
| Prothrombin Time | 3 | 1996 | 36 | 0.070 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2008 | 4 | 0.070 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2012 | 139 | 0.070 |
Why?
|
| Ascaris | 2 | 2018 | 14 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2009 | 111 | 0.070 |
Why?
|
| Internationality | 1 | 2009 | 128 | 0.070 |
Why?
|
| Glutathione | 1 | 2010 | 201 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2011 | 1806 | 0.070 |
Why?
|
| Cathepsin B | 1 | 2008 | 8 | 0.070 |
Why?
|
| Mass Screening | 1 | 2014 | 809 | 0.070 |
Why?
|
| Chromatography, Ion Exchange | 3 | 2004 | 37 | 0.070 |
Why?
|
| Genome, Protozoan | 1 | 2008 | 25 | 0.070 |
Why?
|
| Thinness | 1 | 2008 | 71 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2020 | 1444 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2016 | 488 | 0.070 |
Why?
|
| Interleukin-5 | 2 | 2018 | 50 | 0.070 |
Why?
|
| Cognition | 1 | 2013 | 817 | 0.070 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 154 | 0.070 |
Why?
|
| Monocytes | 2 | 2020 | 336 | 0.070 |
Why?
|
| Antibody Specificity | 3 | 2015 | 164 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 696 | 0.070 |
Why?
|
| Income | 1 | 2008 | 137 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 224 | 0.070 |
Why?
|
| Gerbillinae | 2 | 2018 | 53 | 0.070 |
Why?
|
| Africa, Western | 1 | 2007 | 15 | 0.070 |
Why?
|
| Structural Homology, Protein | 1 | 2007 | 27 | 0.070 |
Why?
|
| Professional Misconduct | 1 | 2007 | 34 | 0.070 |
Why?
|
| Ascitic Fluid | 3 | 1998 | 28 | 0.070 |
Why?
|
| Swine | 2 | 2018 | 1184 | 0.060 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 92 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2008 | 119 | 0.060 |
Why?
|
| Dimerization | 1 | 2007 | 137 | 0.060 |
Why?
|
| Culture Media | 3 | 2014 | 169 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2006 | 759 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2013 | 1073 | 0.060 |
Why?
|
| Hydrolysis | 3 | 2017 | 140 | 0.060 |
Why?
|
| Proteomics | 1 | 2011 | 616 | 0.060 |
Why?
|
| Circular Dichroism | 2 | 2018 | 62 | 0.060 |
Why?
|
| Community Health Services | 1 | 2007 | 86 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 493 | 0.060 |
Why?
|
| Endopeptidases | 2 | 2003 | 106 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 413 | 0.060 |
Why?
|
| Haemonchiasis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Protein Binding | 2 | 2021 | 1655 | 0.060 |
Why?
|
| Climate | 2 | 2020 | 24 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2006 | 184 | 0.060 |
Why?
|
| Caenorhabditis elegans | 2 | 2014 | 245 | 0.060 |
Why?
|
| Diphtheria | 1 | 2025 | 17 | 0.060 |
Why?
|
| Research Design | 2 | 2014 | 715 | 0.060 |
Why?
|
| Chemotactic Factors | 1 | 2005 | 15 | 0.060 |
Why?
|
| Crystallization | 1 | 2005 | 83 | 0.060 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 21 | 0.060 |
Why?
|
| Liver | 2 | 2011 | 1788 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2024 | 13 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 190 | 0.060 |
Why?
|
| Plants, Genetically Modified | 2 | 2015 | 39 | 0.060 |
Why?
|
| Static Electricity | 1 | 2005 | 44 | 0.050 |
Why?
|
| Necator | 1 | 2004 | 2 | 0.050 |
Why?
|
| South Carolina | 1 | 2024 | 10 | 0.050 |
Why?
|
| Food Parasitology | 2 | 2010 | 3 | 0.050 |
Why?
|
| Hemolysin Proteins | 1 | 2004 | 29 | 0.050 |
Why?
|
| Sex Ratio | 1 | 2004 | 12 | 0.050 |
Why?
|
| Louisiana | 1 | 2024 | 137 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 1693 | 0.050 |
Why?
|
| Blotting, Southern | 2 | 2007 | 203 | 0.050 |
Why?
|
| Economics | 1 | 2004 | 12 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 525 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2006 | 708 | 0.050 |
Why?
|
| Lipoprotein Lipase | 1 | 1984 | 60 | 0.050 |
Why?
|
| Trypanosoma brucei brucei | 1 | 1984 | 19 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 2017 | 437 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2024 | 110 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2018 | 1541 | 0.050 |
Why?
|
| Hepatomegaly | 1 | 2023 | 22 | 0.050 |
Why?
|
| Binding Sites | 2 | 2005 | 1136 | 0.050 |
Why?
|
| Substrate Specificity | 4 | 2008 | 285 | 0.050 |
Why?
|
| Proteins | 3 | 2023 | 1008 | 0.050 |
Why?
|
| Pyrantel Pamoate | 2 | 2005 | 2 | 0.050 |
Why?
|
| Health Priorities | 1 | 2004 | 42 | 0.050 |
Why?
|
| PPAR alpha | 1 | 2023 | 54 | 0.050 |
Why?
|
| Protein Transport | 1 | 2025 | 367 | 0.050 |
Why?
|
| Antigens | 2 | 2023 | 104 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 540 | 0.050 |
Why?
|
| Canada | 1 | 2004 | 325 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 364 | 0.050 |
Why?
|
| Microbiology | 1 | 2003 | 7 | 0.050 |
Why?
|
| Education, Public Health Professional | 1 | 2003 | 6 | 0.050 |
Why?
|
| Benzoin | 1 | 2023 | 6 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2004 | 155 | 0.050 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 210 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2004 | 277 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 4031 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 235 | 0.050 |
Why?
|
| Hygiene | 1 | 2003 | 24 | 0.050 |
Why?
|
| Environment | 1 | 2024 | 149 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 600 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2019 | 852 | 0.050 |
Why?
|
| Spleen | 2 | 2015 | 258 | 0.050 |
Why?
|
| Fishes | 2 | 2010 | 33 | 0.050 |
Why?
|
| Viruses | 1 | 2024 | 115 | 0.050 |
Why?
|
| Water | 2 | 2009 | 185 | 0.050 |
Why?
|
| Rabbits | 2 | 2003 | 573 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1485 | 0.050 |
Why?
|
| Perforin | 1 | 2022 | 24 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2002 | 13 | 0.050 |
Why?
|
| Social Justice | 1 | 2023 | 67 | 0.050 |
Why?
|
| Cathepsin D | 1 | 2002 | 16 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 56 | 0.050 |
Why?
|
| Onchocerca | 1 | 2022 | 6 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 500 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 1167 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2003 | 143 | 0.050 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 2004 | 116 | 0.050 |
Why?
|
| Rats, Wistar | 1 | 2003 | 301 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2024 | 510 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2024 | 805 | 0.040 |
Why?
|
| Trypanosoma | 4 | 1982 | 8 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 351 | 0.040 |
Why?
|
| Masks | 1 | 2022 | 37 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2002 | 303 | 0.040 |
Why?
|
| Plasmids | 1 | 2003 | 446 | 0.040 |
Why?
|
| Hybridomas | 1 | 2021 | 30 | 0.040 |
Why?
|
| Florida | 1 | 2021 | 72 | 0.040 |
Why?
|
| Virulence | 2 | 2012 | 271 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2011 | 2423 | 0.040 |
Why?
|
| Blindness | 1 | 2022 | 70 | 0.040 |
Why?
|
| Health Planning | 1 | 2021 | 16 | 0.040 |
Why?
|
| Vibrio cholerae | 1 | 2021 | 33 | 0.040 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2021 | 32 | 0.040 |
Why?
|
| Echocardiography | 2 | 2019 | 1127 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 3355 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 65 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2021 | 101 | 0.040 |
Why?
|
| London | 1 | 2021 | 15 | 0.040 |
Why?
|
| Partial Thromboplastin Time | 2 | 1996 | 55 | 0.040 |
Why?
|
| Synteny | 1 | 2021 | 66 | 0.040 |
Why?
|
| Israel | 1 | 2021 | 47 | 0.040 |
Why?
|
| Zinc | 1 | 2002 | 128 | 0.040 |
Why?
|
| Artemisinins | 1 | 2000 | 8 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 242 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2021 | 52 | 0.040 |
Why?
|
| Body Weight | 1 | 2005 | 983 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 978 | 0.040 |
Why?
|
| Cattle | 1 | 2022 | 502 | 0.040 |
Why?
|
| Sesquiterpenes | 1 | 2000 | 26 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 191 | 0.040 |
Why?
|
| Survival Rate | 2 | 2017 | 2112 | 0.040 |
Why?
|
| Random Allocation | 2 | 2011 | 414 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 515 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2020 | 5033 | 0.040 |
Why?
|
| Serum | 1 | 2020 | 42 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 308 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2018 | 766 | 0.040 |
Why?
|
| Algorithms | 1 | 2007 | 1663 | 0.040 |
Why?
|
| DNA, Protozoan | 1 | 2020 | 26 | 0.040 |
Why?
|
| Cell Line | 2 | 2021 | 2557 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2001 | 181 | 0.040 |
Why?
|
| Neoplasms | 1 | 2015 | 2968 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 59 | 0.040 |
Why?
|
| Reproductive Health Services | 1 | 2020 | 23 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 84 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 26 | 0.040 |
Why?
|
| Muscarinic Agonists | 1 | 2000 | 5 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 289 | 0.040 |
Why?
|
| Parasitology | 1 | 1999 | 7 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3405 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 307 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2020 | 46 | 0.040 |
Why?
|
| Awareness | 1 | 2020 | 79 | 0.040 |
Why?
|
| Expressed Sequence Tags | 1 | 2000 | 77 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 1999 | 24 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1999 | 14 | 0.040 |
Why?
|
| Toxoplasma | 1 | 2020 | 18 | 0.040 |
Why?
|
| Paraguay | 1 | 1999 | 2 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1157 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 396 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 2019 | 40 | 0.040 |
Why?
|
| Models, Immunological | 1 | 1999 | 36 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 1999 | 27 | 0.040 |
Why?
|
| Muscarinic Antagonists | 1 | 2000 | 34 | 0.040 |
Why?
|
| Digestive System | 2 | 2002 | 59 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2020 | 158 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 52 | 0.040 |
Why?
|
| California | 1 | 2019 | 126 | 0.040 |
Why?
|
| Heart Failure | 1 | 2013 | 2323 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 153 | 0.040 |
Why?
|
| Glycoproteins | 4 | 1982 | 343 | 0.040 |
Why?
|
| Neutrophils | 1 | 2001 | 361 | 0.040 |
Why?
|
| Microscopy | 1 | 2020 | 118 | 0.040 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1999 | 3 | 0.040 |
Why?
|
| Social Isolation | 1 | 2019 | 45 | 0.040 |
Why?
|
| Nifurtimox | 1 | 2019 | 3 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 42 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2019 | 137 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 278 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 126 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 173 | 0.040 |
Why?
|
| Parents | 2 | 2019 | 1116 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2899 | 0.040 |
Why?
|
| Awards and Prizes | 1 | 1999 | 62 | 0.040 |
Why?
|
| Health Education | 1 | 2020 | 227 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 114 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 422 | 0.040 |
Why?
|
| Publishing | 2 | 2014 | 108 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2019 | 29 | 0.040 |
Why?
|
| Immunoglobulins | 2 | 2012 | 156 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 215 | 0.040 |
Why?
|
| Swine Diseases | 1 | 2018 | 40 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1999 | 252 | 0.040 |
Why?
|
| Psychology | 1 | 2019 | 61 | 0.040 |
Why?
|
| Panniculitis | 1 | 1998 | 17 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1998 | 37 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 151 | 0.040 |
Why?
|
| Vitamin A | 1 | 2018 | 57 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2018 | 98 | 0.040 |
Why?
|
| Abdominal Muscles | 1 | 1998 | 27 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 171 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2018 | 235 | 0.030 |
Why?
|
| Triose-Phosphate Isomerase | 1 | 1998 | 7 | 0.030 |
Why?
|
| Streptococcus pyogenes | 1 | 1998 | 83 | 0.030 |
Why?
|
| Freezing | 1 | 2017 | 27 | 0.030 |
Why?
|
| Tropomyosin | 1 | 1998 | 26 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2001 | 289 | 0.030 |
Why?
|
| Entamoeba histolytica | 1 | 2017 | 10 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1367 | 0.030 |
Why?
|
| Trans-Activators | 2 | 2011 | 701 | 0.030 |
Why?
|
| Cryptosporidium | 1 | 2017 | 27 | 0.030 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 24 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 1997 | 13 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 2017 | 44 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2018 | 187 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2017 | 41 | 0.030 |
Why?
|
| Vaccine Potency | 1 | 2017 | 9 | 0.030 |
Why?
|
| Curriculum | 1 | 2003 | 790 | 0.030 |
Why?
|
| Drug Storage | 1 | 2017 | 18 | 0.030 |
Why?
|
| Factor XIa | 1 | 2016 | 1 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2018 | 331 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 263 | 0.030 |
Why?
|
| Factor VIIa | 1 | 2016 | 21 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2016 | 9 | 0.030 |
Why?
|
| Factor Xa | 1 | 2016 | 15 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 196 | 0.030 |
Why?
|
| Fluorescence | 1 | 2017 | 94 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2016 | 15 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 243 | 0.030 |
Why?
|
| Software | 1 | 2022 | 731 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2017 | 115 | 0.030 |
Why?
|
| Cross Reactions | 2 | 1996 | 159 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 83 | 0.030 |
Why?
|
| Yemen | 1 | 2016 | 1 | 0.030 |
Why?
|
| Libya | 1 | 2016 | 3 | 0.030 |
Why?
|
| Syria | 1 | 2016 | 9 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 161 | 0.030 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2016 | 11 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2017 | 166 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 485 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2016 | 9 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 731 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 423 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 1996 | 31 | 0.030 |
Why?
|
| Primates | 1 | 2016 | 81 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1610 | 0.030 |
Why?
|
| Streptococcal Infections | 1 | 1998 | 254 | 0.030 |
Why?
|
| Lectins | 1 | 2015 | 50 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 245 | 0.030 |
Why?
|
| Saccharum | 1 | 2015 | 13 | 0.030 |
Why?
|
| Nicaragua | 1 | 2015 | 30 | 0.030 |
Why?
|
| Sigmodontinae | 1 | 2015 | 45 | 0.030 |
Why?
|
| Arthropod Proteins | 1 | 1995 | 13 | 0.030 |
Why?
|
| Phenanthrolines | 1 | 1995 | 2 | 0.030 |
Why?
|
| Zinc Compounds | 1 | 1995 | 6 | 0.030 |
Why?
|
| Hirudins | 1 | 1995 | 39 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 253 | 0.030 |
Why?
|
| Electrophoresis | 1 | 1995 | 32 | 0.030 |
Why?
|
| Ticks | 1 | 1995 | 34 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 148 | 0.030 |
Why?
|
| Caseins | 1 | 1995 | 65 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2020 | 17492 | 0.030 |
Why?
|
| Immunologic Tests | 1 | 2014 | 18 | 0.030 |
Why?
|
| Chlorides | 1 | 1995 | 97 | 0.030 |
Why?
|
| Quality of Life | 1 | 2025 | 2073 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 5152 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 115 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 582 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2016 | 411 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 6420 | 0.030 |
Why?
|
| Intestine, Small | 1 | 2016 | 290 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2014 | 35 | 0.030 |
Why?
|
| Animal Distribution | 1 | 2014 | 13 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2014 | 21 | 0.030 |
Why?
|
| Recreation | 1 | 2014 | 18 | 0.030 |
Why?
|
| Trichomonas Infections | 1 | 2014 | 3 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2014 | 53 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2014 | 28 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 262 | 0.030 |
Why?
|
| Animals, Wild | 1 | 2014 | 33 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 670 | 0.030 |
Why?
|
| European Union | 1 | 2014 | 13 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2016 | 318 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 51 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1995 | 289 | 0.030 |
Why?
|
| Glycosylation | 1 | 2013 | 127 | 0.030 |
Why?
|
| Child Advocacy | 1 | 2013 | 11 | 0.030 |
Why?
|
| Electrophysiology | 1 | 2014 | 249 | 0.030 |
Why?
|
| Excipients | 1 | 2013 | 13 | 0.030 |
Why?
|
| Education, Special | 1 | 2013 | 13 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 1995 | 358 | 0.030 |
Why?
|
| Biophysical Phenomena | 1 | 2013 | 39 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2011 | 4671 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2013 | 39 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2013 | 84 | 0.020 |
Why?
|
| Caregivers | 1 | 2019 | 577 | 0.020 |
Why?
|
| Solubility | 1 | 1993 | 117 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 255 | 0.020 |
Why?
|
| Giardiasis | 1 | 2013 | 11 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 553 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2016 | 298 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 233 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 1933 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 416 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2012 | 68 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 151 | 0.020 |
Why?
|
| Anopheles | 1 | 2012 | 24 | 0.020 |
Why?
|
| Anticestodal Agents | 1 | 2011 | 2 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3029 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 370 | 0.020 |
Why?
|
| Genotype | 1 | 2018 | 2589 | 0.020 |
Why?
|
| Fasciola hepatica | 1 | 2011 | 6 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2011 | 65 | 0.020 |
Why?
|
| Binomial Distribution | 1 | 2011 | 5 | 0.020 |
Why?
|
| Laos | 1 | 2010 | 6 | 0.020 |
Why?
|
| Fish Diseases | 1 | 2010 | 7 | 0.020 |
Why?
|
| Thailand | 1 | 2010 | 47 | 0.020 |
Why?
|
| West Nile Fever | 1 | 2012 | 144 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3744 | 0.020 |
Why?
|
| Anemia, Hypochromic | 1 | 1989 | 5 | 0.020 |
Why?
|
| Mozambique | 1 | 2009 | 21 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2001 | 306 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 1995 | 708 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2014 | 975 | 0.020 |
Why?
|
| Catalysis | 1 | 2009 | 138 | 0.020 |
Why?
|
| Intestinal Mucosa | 2 | 2004 | 762 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2010 | 182 | 0.020 |
Why?
|
| Gelatin | 1 | 2008 | 16 | 0.020 |
Why?
|
| Coumarins | 1 | 2008 | 23 | 0.020 |
Why?
|
| Growth Disorders | 1 | 1989 | 183 | 0.020 |
Why?
|
| Dipeptides | 1 | 2008 | 62 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1209 | 0.020 |
Why?
|
| Endotoxins | 2 | 2004 | 51 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2007 | 28 | 0.020 |
Why?
|
| Satellite Communications | 1 | 2006 | 3 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 92 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 234 | 0.020 |
Why?
|
| Clone Cells | 1 | 2007 | 152 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 134 | 0.020 |
Why?
|
| Quillaja Saponins | 1 | 2005 | 2 | 0.010 |
Why?
|
| Saponins | 1 | 2005 | 20 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 2005 | 23 | 0.010 |
Why?
|
| Cost Control | 1 | 2005 | 22 | 0.010 |
Why?
|
| Social Environment | 1 | 2006 | 112 | 0.010 |
Why?
|
| Phenylenediamines | 1 | 2005 | 29 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 56 | 0.010 |
Why?
|
| Patents as Topic | 1 | 2005 | 18 | 0.010 |
Why?
|
| Private Sector | 1 | 2005 | 26 | 0.010 |
Why?
|
| Amino Acids | 2 | 1985 | 561 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2007 | 436 | 0.010 |
Why?
|
| Weight Loss | 1 | 2009 | 533 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 119 | 0.010 |
Why?
|
| Osmotic Fragility | 1 | 2004 | 2 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 2004 | 19 | 0.010 |
Why?
|
| Cachexia | 1 | 1985 | 57 | 0.010 |
Why?
|
| Hemolysis | 1 | 2004 | 87 | 0.010 |
Why?
|
| Serial Passage | 1 | 2003 | 19 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 124 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2004 | 236 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 348 | 0.010 |
Why?
|
| Elastic Tissue | 1 | 1983 | 18 | 0.010 |
Why?
|
| Mutation | 1 | 2017 | 6094 | 0.010 |
Why?
|
| DNA, Circular | 1 | 2003 | 17 | 0.010 |
Why?
|
| Yeasts | 1 | 2003 | 43 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1983 | 44 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1983 | 39 | 0.010 |
Why?
|
| Insecta | 1 | 2003 | 46 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1989 | 1086 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 1793 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2001 | 18 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1984 | 499 | 0.010 |
Why?
|
| Plasmodium | 1 | 2000 | 10 | 0.010 |
Why?
|
| Fertility | 1 | 2003 | 260 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2289 | 0.010 |
Why?
|
| Macrophages | 1 | 1985 | 660 | 0.010 |
Why?
|
| Arecoline | 1 | 2000 | 1 | 0.010 |
Why?
|
| Oxotremorine | 1 | 2000 | 1 | 0.010 |
Why?
|
| Pilocarpine | 1 | 2000 | 10 | 0.010 |
Why?
|
| Atropine | 1 | 2000 | 29 | 0.010 |
Why?
|
| Pyrantel | 1 | 1999 | 1 | 0.010 |
Why?
|
| RNA, Helminth | 1 | 1999 | 10 | 0.010 |
Why?
|
| Glycogen | 1 | 1999 | 51 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 2000 | 137 | 0.010 |
Why?
|
| Neuropeptides | 1 | 2000 | 110 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 194 | 0.010 |
Why?
|
| Immunocompetence | 1 | 1998 | 31 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 308 | 0.010 |
Why?
|
| Isoelectric Focusing | 3 | 1982 | 22 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 1383 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1998 | 143 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2000 | 776 | 0.010 |
Why?
|
| Thromboplastin | 1 | 1996 | 17 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1993 | 251 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1993 | 2060 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1985 | 95 | 0.000 |
Why?
|
| Macrophage Activation | 1 | 1985 | 66 | 0.000 |
Why?
|
| Hyperlipidemias | 1 | 1985 | 186 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1985 | 636 | 0.000 |
Why?
|
| Agglutination Tests | 1 | 1982 | 8 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1982 | 82 | 0.000 |
Why?
|
| Isoelectric Point | 1 | 1981 | 16 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1982 | 140 | 0.000 |
Why?
|
| Lactoperoxidase | 1 | 1981 | 1 | 0.000 |
Why?
|
| Tsetse Flies | 1 | 1981 | 1 | 0.000 |
Why?
|
| Trypanosomiasis, African | 1 | 1981 | 3 | 0.000 |
Why?
|
| Trypsin | 1 | 1981 | 68 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1981 | 181 | 0.000 |
Why?
|
| Genes, Synthetic | 1 | 1981 | 13 | 0.000 |
Why?
|
| Brain | 1 | 1993 | 3174 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1981 | 263 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1981 | 296 | 0.000 |
Why?
|
| Recurrence | 1 | 1981 | 1469 | 0.000 |
Why?
|